GaryMasonMD

Pediatric Hematology & Oncology • Spring House, PA

Pediatric Neuro-Oncology

Senior Medical Director, Oncology Janssen

Join to view full profile

Dr. Mason is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Mason's full profile

Already have an account?

Office
1400 McKean Road
Spring House, PA 19477

Education & Training

Children's National Medical Center/George Washington UniversityFellowship, Pediatric Neuro-Oncology, 2013 - 2014
New York Presbyterian Hospital (Cornell Campus)Fellowship, Pediatric Hematology/Oncology, 2010 - 2013
Brown UniversityResidency, Pediatrics, 2007 - 2010
Albert Einstein College of MedicineClass of 2007

Certifications & Licensure

PA State Medical License 2014 - 2024
DC State Medical License 2013 - 2014
NY State Medical License Active through 2013
American Board of Pediatrics Pediatrics

Clinical Trials

Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors Start of enrollment: 2015 Jul 14
Completed
Phase 1
Panobinostat in Treating Younger Patients With Progressive Diffuse Intrinsic Pontine Glioma Start of enrollment: 2016 Apr 01

Publications & Presentations

PubMed

2 citations
Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and ...
Matthew R Smith, Shahneen Sandhu, Daniel J George, Kim Nguyen Chi, Fred Saad
Journal of Managed Care & Specialty Pharmacy. 2023-07-01
102 citations
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial.
Matthew R Smith, Howard I Scher, Shahneen Sandhu, Eleni Efstathiou, Primo N Lara Jr
The Lancet. Oncology. 2022-03-01
16 citations
Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant...
Charles G. Drake, Russell K. Pachynski, Sumit K. Subudhi, Douglas G. McNeel, Emmanuel S. Antonarakis
Prostate Cancer and Prostatic Diseases. 2021-07-13

Journal Articles

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
Kim N Chi, Dana Rathkopf, Matthew R Smith, Eleni Efstathiou, Gerhardt Attard, David Olmos, Ji Youl Lee, Eric J Small, Andrea J Pereira de Santana Gomes, Guilhem Roubau..., J Clin Oncol ., 3/23/2023